While REITs appear to be appropriately valued as a basket, 2018 looks to be an exciting year for selective REIT investment as mispricing is rampant, and there are quite a few REITs that have both cheap valuation and strong fundamentals. Among the handful of REITs with outsized reward to risk, UMH Properties (UMH) stands out as our top pick going into 2018.
The Buy Thesis
UMH is positioned to capture the economic growth of middle America. Prima facie, there are quite a few REITs, such as industrial and apartment REITs that could potentially benefit from this growth, but subtle aspects of industry structure set UMH apart from a value capture perspective. Where others will get some growth, UMH is uniquely positioned to capture massive growth. Despite the favorable fundamental outlook, this small cap manufactured housing REIT is priced at a multiple below that of the average REIT.
Quite simply, top tier growth at the price of a slightly below average multiple = outsized reward for the risk.
Best Growth Stocks For 2018: Synacor, Inc.(SYNC)
- [By Lisa Levin]
Synacor Inc (NASDAQ: SYNC) shares dropped 18 percent to $3.42. Synacor priced 5.715 million shares at $3.50 per share.
Shares of Resources Connection, Inc. (NASDAQ: RECN) were down around 15 percent to $13.65 after the company posted downbeat quarterly results.
- [By Monica Gerson]
Synacor Inc (NASDAQ: SYNC) is projected to post a quarterly loss at $0.03 per share on revenue of $30.00 million.
VAALCO Energy, Inc. (NYSE: EGY) is expected to post a quarterly loss at $0.11 per share on revenue of $18.59 million.
Best Growth Stocks For 2018: SPDR Blmbg Barclays Em Mkts Lcl Bd ETF (EBND)
- [By Todd Shriber, ETF Professor]
DWFI also holds the SPDR Barclays Emerging Markets Local Bond ETF (NYSE: EBND), SPDR Barclays International Treasury Bond ETF (NYSE: BWX) and the SPDR Barclays Intermediate Term Corporate Bond ETF (NYSE: ITR).
Best Growth Stocks For 2018: Alder BioPharmaceuticals, Inc.(ALDR)
- [By Paul Ausick]
Alder Biopharmaceuticals Inc. (NASDAQ: ALDR) posted a new 52-week low of $13.50on Tuesday, down nearly 28% compared with Monday’s closing price of $18.70. The stock’s 52-week high is $36.48. Volume totaled more than 12 million shares, about 12 times the daily average of around 720,000. The company reported that its migraine treatment reported a positive result, but investors were not impressed.